Biotech Startup PetDx Raises $62M Series B to Increase Adoption of Multi-Cancer Early Detection Test for Dogs

PetDx, a molecular diagnostics company, that uses genomic information to improve pet health recently ANNOUNCED the completion of a $62 million Series B funding round led by Longview Asset Management LLC (the investment firm also made prior investments in Chewy, Petsmart, Fi, and Wedgewood Pharmacy).

The new funding will be used to broaden the adoption of OncoK9, a first-in-class multi-cancer early detection (MCED) test that employs next-generation sequencing (NGS) to detect many types of cancer in dogs with a simple blood draw. It will also enable PetDx to expand testing throughput at the company’s central laboratory in San Diego, accelerate its R&D roadmap and deliver sooner on its full scientific vision for the detection, characterization, and management of cancer in companion animals.

Cancer is by far the leading cause of death in dogs, with approximately six million new cases diagnosed each year in the United States alone. There are currently no established cancer screening programs for dogs.


  • PetDx Launches New Multi-Cancer Screening Test for Dogs (6.2.21)

    • PetDx recommends OncoK9 as an annual screening test for dogs that are 8 years or older and or belong to breeds that are highly predisposed to cancer. The test is available by prescription only.

In August 2020, PetDx raised $10 million Series A funding led by Friedman Bioventure with participation from the Petco Health and Wellness Company Inc (NASDAQ: WOOF) and an undisclosed leading pet healthcare company.

Veterinary Cancer Society (VCS):

  • VCS is a non-profit educational organization consisting of nearly 1,000 specialists in medical, surgical, and radiation oncology, internists, pathologists, pharmacologists and general practitioners from around the world.